Cho JY(1), Gupta S(2), Cho HS(3)(4), Park MS(4), Mok SJ(5), Han I(3)(5), KimHS(3)(5).
(1)Dept of Surgery, Lin Women's Hospital, Seoul, Korea.(2)Division of Orthopaedic Surgery, Glasgow Royal Infirmary, Glasgow, UK (3)Dept of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea. (4)Dept of Orthopedic Surgery, Seoul National University Bundang Hospital, Seongnam, Korea. (5)Dept of Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea.
Publication
Clin Orthop Surg
Summary
We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables. Twenty patients treated with meloxicam were followed up every 3 to 6 months. Meloxicam administration was planned at 15 mg/day orally for 6 months. Of the 20 patients evaluated, according to Response Evaluation Criteria in Solid Tumors criteria, there were five patients with partial response (25.0%), eight with stable disease (40.0%), and seven with tumor progression (35.0%). The present study suggests that conservative treatment would be a primary treatment option for this perplexing disease even though we were not able to determine that the use of a cyclooxygenase-2 inhibitor would have an additional influence on the natural course of a desmoid tumor.
Stay Up to Date as We Uncover More About Desmoid Tumors
